EN DE
Watch Ginkgo Bioworks Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ginkgo Bioworks Holdings (DNA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Ginkgo Bioworks Holdings stock $4.64, price $11.29, that is 58.9% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

GB Ginkgo Bioworks Holdings logo Thin data Nov 8, 2026

Ginkgo Bioworks Holdings

DNA · US
Very expensive, weak quality

Our calculation puts a fair price 59% below what the stock costs today.

Insiders sold $970,976 (6M)
Revenue last quarter 29% below a year ago.
Fair value $4.64 · Strongly overvalued
Quality 30/100
Weak Growth (revenue 3y −29.1 %/yr in USD)
Loss-making · -192.0% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 13/100
Thin data
⚠ Dilution
Watch Ginkgo Bioworks Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$596.80 $5.36 Fair Value $4.64 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $5.36 – $596.80 · fair‑value band $3.47 – $6.94 · the $11.29 price screens above the $4.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Ginkgo Bioworks in your weekly email

Every Wednesday you see whether Ginkgo Bioworks is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.

Show moreShow less

The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.

It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats.

In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization.

The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stock analysis

Ginkgo Bioworks Holdings (DNA) currently trades at $11.29, while our model-based Fair Value estimate is $4.64, 59% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $3.47 (bear) to $6.94 (bull), the price of $11.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Ginkgo Bioworks Holdings reported revenue of $170M in FY2025 versus $314M in FY2021, a compound −14.2%/yr. Reported net income was −$313M in FY2025.

Key figures

Market cap $760M Small · P/S ratio 5.81 · EPS (TTM) $−4.24 · Return on equity −58.2% · Return on assets (EBIT) −59.2% (5-year average) · Operating margin −157% · Revenue (TTM) $131M · Revenue growth (YoY) −28.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).

What moves the price

The share trades about 25% below its 52-week high and 106% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −59%, DNA screens richer than that median.

Fair Value models

Bear $3.47 Fair Value $4.64 Bull $6.94
Price $11.29 · Downside -58.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $4.08 $5.46 $8.16 51
All 1 models by family
Asset-Based
NCAV (Graham) $4.08 $5.46 $8.16 51

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $970,976 and none bought.

  • SaleJason R KellyOfficer, Director2× since Apr 8, 2026: 252,464 shares, avg. $7.28$1.8MOct 19, 2026
  • SaleReshma P. ShettyOfficer, Director, 10% owner3× since Apr 8, 2026: 192,170 shares, avg. $7.26$1.4MOct 19, 2026
  • SaleBarry Canton10% owner3× since Apr 8, 2026: 192,170 shares, avg. $7.26$1.4MOct 19, 2026
  • SaleSteven P. CoenOfficer10× since Dec 15, 2025: 40,469 shares, avg. $7.16$289,803Oct 19, 2026
  • SaleChristian O HenryDirector5,000 shares at $7.08$35,400Sep 15, 2026

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−25.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−178.8% (2020) → −185.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DNA screens overvalued: fair value 59% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Ginkgo Bioworks Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −58.9% · Below median
Profitability
Return on assets −27.9% · Below median
Net margin (12 months) −192.0% · Bottom 25%
Operating margin (12 months) −157.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.49× · Cheaper than median
P/S (12 months) 5.82× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs DNA
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs DNA
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs DNA
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs DNA
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs DNA
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs DNA
argenx SE ARGX $927.21 $908.40 −2% vs DNA
CSL Limited CSL A$200.77 A$183.04 −9% vs DNA
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs DNA
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs DNA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ginkgo Bioworks Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ginkgo Bioworks Holdings Fair Value". https://www.fairvalue-calculator.com/stock/DNA

Frequently asked questions

Is Ginkgo Bioworks Holdings (DNA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $4.64 versus a price of $11.29, about 59% lower (overvalued).
What is the fair value of DNA?
Our model-based fair value for Ginkgo Bioworks Holdings is $4.64 (as of Nov 8, 2026), built from audited fundamentals. The current price: $11.29.
What is the quality score of DNA?
Ginkgo Bioworks Holdings has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ginkgo Bioworks Holdings (DNA)?
Our model-based price target is the fair value of $4.64 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $3.47, optimistic scenario $6.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Ginkgo Bioworks Holdings stock forecast for 2026?
Our models put fair value at $4.64, about 59% lower versus a price of $11.29 (overvalued). Cautious scenario $3.47, optimistic scenario $6.94. The calculation is refreshed regularly with new filings.
What is the revenue of Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings reported trailing-twelve-month revenue of about $131M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Ginkgo Bioworks Holdings (DNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ginkgo Bioworks Holdings it is $4.64 per share (as of Nov 8, 2026), against a price of $11.29. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Ginkgo Bioworks Holdings stock overvalued or undervalued in 2026?
As of Nov 8, 2026, DNA trades above its calculated fair value: price $11.29, fair value $4.64, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DNA?
No. The price is what the market pays today ($11.29); the fair value is what the company's own numbers justify ($4.64). For Ginkgo Bioworks Holdings the two are $6.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ginkgo Bioworks Holdings worth?
The market values Ginkgo Bioworks Holdings at about $760M (market capitalisation, as of Nov 8, 2026). Per share that is $11.29; our models calculate a fair value of $4.64 per share.
What do the bullish and bearish scenarios say about DNA?
Our models span a range for Ginkgo Bioworks Holdings: cautious scenario $3.47, base $4.64, optimistic $6.94 per share (as of Nov 8, 2026, price $11.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ginkgo Bioworks Holdings (DNA)?
Balance-sheet figures for Ginkgo Bioworks Holdings (as of Nov 8, 2026): return on equity −58.2%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is DNA from its 52-week high?
Ginkgo Bioworks Holdings trades at $11.29, about 25% below its 52-week high of $14.98 and 106% above the low of $5.48 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.64 is for.
Which stocks are comparable to Ginkgo Bioworks Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ginkgo Bioworks Holdings stock attractive at the current price?
The data as of Nov 8, 2026: price $11.29, calculated fair value $4.64 (−59%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DNA calculated?
We run Ginkgo Bioworks Holdings through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $4.64 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ginkgo Bioworks Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ginkgo Bioworks Holdings (DNA)?
The closing price on Nov 6, 2026 was $11.29. Our model-based fair value is $4.64, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ginkgo Bioworks Holdings right now?
The price sits above even our optimistic bull case ($6.94). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.47 to $6.94) leaves room in how you read the outcome.

Key figures of Ginkgo Bioworks Holdings

How large is the market capitalisation of Ginkgo Bioworks Holdings (DNA)?
The market capitalisation of Ginkgo Bioworks Holdings is $760M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ginkgo Bioworks Holdings (DNA)?
The price-to-sales ratio of Ginkgo Bioworks Holdings is 5.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ginkgo Bioworks Holdings (DNA)?
Earnings per share at Ginkgo Bioworks Holdings are $−4.24. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Ginkgo Bioworks Holdings (DNA)?
The return on equity (ROE) of Ginkgo Bioworks Holdings is −58.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ginkgo Bioworks Holdings (DNA)?
On an EBIT basis the return on assets of Ginkgo Bioworks Holdings is −59.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ginkgo Bioworks Holdings (DNA)?
The operating margin of Ginkgo Bioworks Holdings is −157% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ginkgo Bioworks Holdings (DNA)?
Revenue at Ginkgo Bioworks Holdings is growing −28.6% versus a year earlier (3y avg −29.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ginkgo Bioworks Holdings (DNA) generate?
The free cash flow of Ginkgo Bioworks Holdings is −$179M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ginkgo Bioworks Holdings (DNA) carry?
The net debt of Ginkgo Bioworks Holdings is $273M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ginkgo Bioworks Holdings in the live analysis

One click puts Ginkgo Bioworks Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.